ChenGuang Biotech Group Co., Ltd. (SHE:300138)
China
· Delayed Price · Currency is CNY 14.50
+0.40 (2.84%)
At close: Mar 9, 2026
ChenGuang Biotech Group Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 6,564 | 5,803 | 5,671 | 5,074 | 3,950 | Upgrade
|
| Other Revenue | - | 1,191 | 1,200 | 1,222 | 923.77 | Upgrade
|
| Revenue | 6,564 | 6,994 | 6,872 | 6,296 | 4,874 | Upgrade
|
| Revenue Growth (YoY) | -6.15% | 1.79% | 9.14% | 29.18% | 24.55% | Upgrade
|
| Cost of Revenue | - | 6,535 | 6,072 | 5,452 | 4,175 | Upgrade
|
| Gross Profit | 6,564 | 459.36 | 799.37 | 843.87 | 698.53 | Upgrade
|
| Selling, General & Admin | - | 208.33 | 213.08 | 249.21 | 210.35 | Upgrade
|
| Research & Development | - | 128.6 | 97.4 | 129.03 | 94.79 | Upgrade
|
| Other Operating Expenses | 6,125 | -1.78 | 7.09 | 16.82 | 13.66 | Upgrade
|
| Operating Expenses | 6,125 | 335.27 | 318.45 | 395.16 | 319.48 | Upgrade
|
| Operating Income | 438.91 | 124.1 | 480.92 | 448.71 | 379.05 | Upgrade
|
| Interest Expense | - | -114.42 | -83.51 | -67.21 | -53.15 | Upgrade
|
| Interest & Investment Income | - | 58.36 | 104.28 | 63.27 | 39.58 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 5.54 | 2.41 | 21.37 | -5.63 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.51 | -7.66 | 3.31 | -2.36 | 7.61 | Upgrade
|
| EBT Excluding Unusual Items | 440.42 | 65.92 | 507.43 | 463.78 | 367.46 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -5.11 | 5.36 | -5.02 | 0.56 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 4.89 | -0.63 | 1.08 | 0.1 | Upgrade
|
| Asset Writedown | - | -0.46 | -1.1 | -1.32 | -10.91 | Upgrade
|
| Other Unusual Items | - | 41.71 | 44.76 | 43.24 | 40.85 | Upgrade
|
| Pretax Income | 440.42 | 106.95 | 555.82 | 501.76 | 398.07 | Upgrade
|
| Income Tax Expense | 76.77 | 28.99 | 61.65 | 65.67 | 47.47 | Upgrade
|
| Earnings From Continuing Operations | 363.65 | 77.96 | 494.17 | 436.09 | 350.6 | Upgrade
|
| Minority Interest in Earnings | - | 16.09 | -14.45 | -2.05 | 0.92 | Upgrade
|
| Net Income | 363.65 | 94.05 | 479.72 | 434.03 | 351.51 | Upgrade
|
| Net Income to Common | 363.65 | 94.05 | 479.72 | 434.03 | 351.51 | Upgrade
|
| Net Income Growth | 286.65% | -80.40% | 10.53% | 23.47% | 31.29% | Upgrade
|
| Shares Outstanding (Basic) | 476 | 517 | 532 | 533 | 529 | Upgrade
|
| Shares Outstanding (Diluted) | 476 | 517 | 532 | 533 | 529 | Upgrade
|
| Shares Change (YoY) | -8.00% | -2.76% | -0.14% | 0.80% | 4.13% | Upgrade
|
| EPS (Basic) | 0.76 | 0.18 | 0.90 | 0.81 | 0.67 | Upgrade
|
| EPS (Diluted) | 0.76 | 0.18 | 0.90 | 0.81 | 0.67 | Upgrade
|
| EPS Growth | 320.30% | -79.84% | 10.68% | 22.49% | 26.09% | Upgrade
|
| Free Cash Flow | - | -372.35 | -777.67 | 558.78 | -216.92 | Upgrade
|
| Free Cash Flow Per Share | - | -0.72 | -1.46 | 1.05 | -0.41 | Upgrade
|
| Dividend Per Share | - | 0.130 | 0.130 | 0.160 | 0.130 | Upgrade
|
| Dividend Growth | - | - | -18.75% | 23.08% | 30.00% | Upgrade
|
| Gross Margin | 100.00% | 6.57% | 11.63% | 13.40% | 14.33% | Upgrade
|
| Operating Margin | 6.69% | 1.77% | 7.00% | 7.13% | 7.78% | Upgrade
|
| Profit Margin | 5.54% | 1.34% | 6.98% | 6.89% | 7.21% | Upgrade
|
| Free Cash Flow Margin | - | -5.32% | -11.32% | 8.88% | -4.45% | Upgrade
|
| EBITDA | 605.12 | 290.31 | 633.47 | 593.27 | 509.67 | Upgrade
|
| EBITDA Margin | 9.22% | 4.15% | 9.22% | 9.42% | 10.46% | Upgrade
|
| D&A For EBITDA | 166.22 | 166.22 | 152.54 | 144.56 | 130.62 | Upgrade
|
| EBIT | 438.91 | 124.1 | 480.92 | 448.71 | 379.05 | Upgrade
|
| EBIT Margin | 6.69% | 1.77% | 7.00% | 7.13% | 7.78% | Upgrade
|
| Effective Tax Rate | 17.43% | 27.11% | 11.09% | 13.09% | 11.92% | Upgrade
|
| Revenue as Reported | - | 6,994 | 6,872 | 6,296 | 4,874 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.